… of PSA response with OS and rPFS using PSA response as a … model confirmed the trend
that PSA responders tend to have … of PSA responses measured by PSA50 response, PSA90 …

… One such drug is abiraterone acetate (AA). AA treatment inhibits androgen synthesis at the
cellular level by blocking the CPY17A1 enzyme. In the absence of androgens, the levels of …

… PSA kinetics, especially early PSA response, and outcome to AA after progression to
docetaxel. Taken together with other factors, lack of an early PSA response could identify patients …

… related with increased survival [6] [7] [8] [9] [10]. Recently, two studies that exclusively analyzed
mHSPC patients added the variable of a decrease in PSA … changes in PSA because this …

… Three clinical end points regarding treatment response were … ; PSA response, PSA independent
PFS, and time to PSA … , 62 patients on treatment with abiraterone acetate were included …

… PSA achieved, PSAD and ⩽5 bone metastasis, NLR and <5 skeletal metastasis were independent
predictors of better response … of abiraterone were also not related to drug response in …

… response to intravesical Bacillus Calmette-Guerin immunotherapy and was associated with
preferable prognosis in patients … to be associated with PSA progression in mHSPC patients …

… with abiraterone acetate and prednisone (AA+P) in patients with … Patients and Methods:
Patients diagnosed with mCPRC not … , the patients in the present study presented with PSA, AP …

… of % decrease in PSA at 3 months is associated with time to CRPC. … clinical significance of
ADT with abiraterone acetate in comparison with bicalutamide for high-risk mHSPC patients in …

… in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone
acetate … hormonal therapies, as abiraterone acetate (AA), the role of PSA as a surrogate …